Combadière Behazine, Mahé Brice
Institut National de la Santé et de la Recherche Médicale (INSERM) U543, Université Pierre et Marie Curie-Paris6, 91 Boulevard de l'Hôpital, 75634 Paris, France.
Comp Immunol Microbiol Infect Dis. 2008 Mar;31(2-3):293-315. doi: 10.1016/j.cimid.2007.07.015. Epub 2007 Oct 30.
Immunization concepts evolve with increasing knowledge of how the immune system works and the development of new vaccination methods. Traditional vaccines are made of live, attenuated, killed or fragmented pathogens. New vaccine strategies can take advantage of particulate compounds--microspheres or nanoparticles--to target antigen-presenting cells better, which must subsequently reach the secondary lymphoid organs, which are the sites of the immune response. The use of the skin as a target organ for vaccine delivery stems from the fact that immature dendritic cells (DCs), which are professional antigen-presenting cells can be found at high density in the epidermis and dermis of human or animal skin. This has led to design various methods of dermal or transcutaneous vaccination. The quality and duration of the humoral and cellular responses to vaccination depend on the appropriate targeting of antigen-presenting cells, of the vaccine dose, route of administration and use of adjuvant. In this review, we will focus on the use of micro- and nano-particles to target the skin antigen-presenting cells and will discuss recent advances in the field of transcutaneous vaccination in animal models and humans.
随着对免疫系统工作方式的了解不断深入以及新疫苗接种方法的发展,免疫概念也在不断演变。传统疫苗由减毒活病原体、灭活病原体或病原体片段制成。新的疫苗策略可以利用微粒化合物——微球或纳米颗粒——来更好地靶向抗原呈递细胞,这些细胞随后必须到达二级淋巴器官,而二级淋巴器官是免疫反应发生的部位。将皮肤作为疫苗递送的靶器官,是因为在人和动物皮肤的表皮和真皮中可以高密度地发现未成熟的树突状细胞(DCs),而树突状细胞是专职抗原呈递细胞。这促使人们设计了各种真皮或经皮接种疫苗的方法。疫苗接种后体液和细胞免疫反应的质量和持续时间取决于抗原呈递细胞的适当靶向、疫苗剂量、给药途径以及佐剂的使用。在本综述中,我们将重点关注使用微米和纳米颗粒靶向皮肤抗原呈递细胞,并讨论动物模型和人类经皮接种疫苗领域的最新进展。